Research 'backs watchful waiting' in prostate cancer
8/16/2013
Prostate cancer researchers publishing in the Cancer Research journal argue for more watchful waiting to manage the disease, rather than moving straight to aggressive treatment or surgery. "Radical prostatectomy or radiation therapy, the usual treatments for prostate cancer, can have negative side-effects such as impotence and incontinence," the lead researcher said...
"Reprogrammed" treatment-resistant lymphomas respond to cancer drugs
8/16/2013
A phase I clinical trial showed diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy can be reprogrammed to respond to treatment using the drug azacitidine, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research...
Pfizer Ltd has expressed concern and disappointment that the final appraisal determination (FAD) from the National Institute of Health and Care Excellence (NICE) does not recommend Xalkori (crizotinib) for previously treated, ALK positive advanced non small cell lung cancer (NSCLC)...
Pfizer Ltd has expressed concern and disappointment that the final appraisal determination (FAD) from the National Institute of Health and Care Excellence (NICE) does not recommend Xalkori (crizotinib) for previously treated, ALK positive advanced non small cell lung cancer (NSCLC)...
International team reveals 21 'signatures' in 30 common cancers
8/16/2013
An international team, including scientists from Sydney's Garvan Institute of Medical Research and The University of Queensland, has described the mutational processes that drive tumour development in 30 of the most common cancer types. The discovery, published in Nature, one of the world's leading scientific journals, could help to treat and prevent a wide range of cancers...
Purdue innovation could improve personalized cancer-care outcomes
8/16/2013
An innovation created by Purdue University researchers could improve therapy selection for personalized cancer care by helping specialists better identify the most effective drug treatment combinations for patients. David D. Nolte, a professor in Purdue's Department of Physics, and his collaborators Ran An, a graduate student in physics, and John J...
Moffitt Cancer Center researchers suggest secondary cancers seen in melanoma patients who are being treated for a BRAF gene mutation may require new strategies, such as enhanced surveillance and combining BRAF-inhibitor therapy with other inhibitors, especially as they become more widely used...
A team of researchers from UC Davis, UC San Diego and other institutions has identified a key mechanism behind aggressive prostate cancer. Published on August 14, 2013 in Nature, the study shows that two long non-coding RNAs (PRNCR1 and PCGEM1) activate androgen receptors, circumventing androgen-deprivation therapy...
Invasive breast cancer surgery increasing with growing use of MRIs
8/16/2013
Heavy use of magnetic resonance imaging (MRI) may be leading to unnecessary breast removal in older women with breast cancer, according to a study by Yale School of Medicine researchers in the current issue of Breast Cancer Research and Treatment...
Reducing prostate cancer risk safely with finasteride
8/16/2013
A long-term follow-up to a groundbreaking study led by the director of the Cancer Therapy & Research Center confirms that a drug shown to reduce risk of prostate cancer by more than a third has no impact on lifespan but further reduces the risk of prostate cancer...